Preclinical News and Research

RSS

New therapeutic option for HPV-positive head and neck carcinoma discovered

The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell carcinoma (HNSCC) is caused by human papillomavirus (HPV) and, currently, is not always treatable.

19 Apr 2022

Noninvasive sound technology could lead to improved cancer outcomes in humans

Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread—an advance that could lead to improved cancer outcomes in humans.

18 Apr 2022

Maternal exercise during pregnancy improves metabolic health of offspring, shows study

A new study has demonstrated that maternal exercise during pregnancy improves the metabolic health of offspring, even when the mother is obese or on a high-fat diet.

14 Apr 2022

Orally delivered temperature-stable tablet vaccine efficacy against SARS-CoV-2 and other respiratory infections

Researchers assessed the protective efficacy of the temperature-stable orally delivered vaccines against respiratory viral pathogens.

14 Apr 2022

The preclinical potential of S. miltiorrhiza extracts for the treatment of COVID-19

In a recent study, researchers assessed the anti-COVID-19 efficacy of Salvia miltiorrhiza Bunge.

14 Apr 2022

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

Reaction Biology, an industry-leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

From Reaction Biology Corporation 13 Apr 2022

Researchers elucidate how ovarian tumors defy immunotherapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and elsewhere, have further elucidated how ovarian cancer tumors defy immunotherapy, identifying new molecular targets that might boost immune response.

12 Apr 2022

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

A recent article posted to the bioRxiv* preprint server illustrated that the activation of the Hippo signaling pathway upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection aids the host antiviral response.

11 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

New instrument will help Columbia scientists to study heavy ion radiation therapy

Heavy ions could radically improve radiation therapy for treatment of pancreatic cancer and other difficult-to-treat tumors if researchers can better understand how the ions work against cancer.

11 Apr 2022

What does the Future of Microfluidics within Research Look Like?

We speak to France Hamber, CEO of Fluigent, about their microfluidics solutions and how they are allowing scientists to focus more on the science than the setup.

From Fluigent 11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Novel therapy advances to clinical trial for the treatment of glioblastoma

A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

10 Apr 2022

New delivery method enhances the "attack power" of CAR T cells against tumors

One cutting-edge cancer treatment exciting researchers today involves collecting and reprogramming a patient's T cells – a special set of immune cells – then putting them back into the body ready to detect and destroy cancerous cells.

8 Apr 2022

SARS-CoV-2 Omicron variant spike-specific unique cluster of differentiation cells

A new study presented a safe and efficient multi-epitope SARS-CoV-2 vaccine construct against SARS-CoV-2 variants, including Omicron.

8 Apr 2022

Researchers design RNA molecules for delivering therapies directly to beta cells

Investigators at the University of Miami Miller School of Medicine have designed RNA molecules that home to human pancreatic beta cells, the cells that produce insulin and are destroyed in patients with type 1 and type 2 diabetes.

7 Apr 2022

An assessment of COVID-19 vaccine safety during pregnancy

In a recent study posted to the Preprints with The Lancet* SSRN preprint server, researchers evaluated the safety of currently administered coronavirus disease 2019 (COVID-19) vaccines in child-bearing women.

7 Apr 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022

Preclinical News and Research

New therapeutic option for HPV-positive head and neck carcinoma discovered

Noninvasive sound technology could lead to improved cancer outcomes in humans

Maternal exercise during pregnancy improves metabolic health of offspring, shows study

Orally delivered temperature-stable tablet vaccine efficacy against SARS-CoV-2 and other respiratory infections

The preclinical potential of S. miltiorrhiza extracts for the treatment of COVID-19

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

Researchers elucidate how ovarian tumors defy immunotherapy

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

New study reveals oral opaganib's potent in vitro activity against Omicron

New instrument will help Columbia scientists to study heavy ion radiation therapy

What does the Future of Microfluidics within Research Look Like?

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

Novel therapy advances to clinical trial for the treatment of glioblastoma

New delivery method enhances the "attack power" of CAR T cells against tumors

SARS-CoV-2 Omicron variant spike-specific unique cluster of differentiation cells

Researchers design RNA molecules for delivering therapies directly to beta cells

An assessment of COVID-19 vaccine safety during pregnancy

Developing and manufacturing custom recombinant antibodies for R&D

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics